Roy Buchanan Analyst PerformanceAnalyst at Citizens JmpRoy Buchanan is a stock analyst at Citizens Jmp focused in the medical sector, covering 16 publicly traded companies. Over the past year, Roy Buchanan has issued 15 stock ratings, including and buy recommendations. While full access to Roy Buchanan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Roy Buchanan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings49 Last 10 YearsBuy Recommendations93.48% 43 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution46RatingsDistribution of strong buy, buy, hold, and sell ratings by Roy Buchanan.RatingPercentageCount Strong Buy0.0%0 ratings Buy93.5%43 ratings Hold6.5%3 ratings Sell0.0%0 ratingsOut of 46 total stock ratings issued by Roy Buchanan at Citizens Jmp, the majority (93.5%) have been Buy recommendations, followed by 6.5% Hold.Best & Worst CallsBest Call000000.0%ABVXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NVUSApr 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ16 companiesRoy Buchanan, an analyst at Citizens Jmp, currently covers 16 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies87.5%Finance1 company6.3%Manufacturing1 company6.3%Roy Buchanan of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Finance and Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies37.5%MED - DRUGS5 companies31.3%PHARMACEUTICAL PREPARATIONS4 companies25.0%FIN - INVEST MGMT1 company6.3% Roy Buchanan's Ratings History at Citizens Jmp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCDTXCidara Therapeutics10/3/2025Set Price Target$98.50$173.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics9/24/2025Set Price Target$88.30$153.00$0.0000.00% ROIDVAXDynavax Technologies8/22/2025Reiterated Rating$10.95$32.00Market Outperform$0.0000.00% ROIENTAEnanta Pharmaceuticals8/12/2025Boost Price Target$6.49$25.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics8/8/2025Boost Price Target$61.60$66.00Market Outperform$0.0000.00% ROIDVAXDynavax Technologies8/8/2025Boost Price Target$10.15$32.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics6/30/2025Reiterated Rating$49.45$59.00Market Outperform$0.0000.00% ROIPYPDPolyPid6/17/2025Lower Price Target$3.53$14.00Market Outperform$0.0000.00% ROIENTAEnanta Pharmaceuticals6/3/2025Boost Price Target$7.09$24.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics6/2/2025Reiterated Rating$21.56$47.00Market Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CVACCureVac5/28/2025Reiterated Rating$4.38$10.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics5/27/2025Reiterated Rating$24.28$47.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics5/9/2025Boost Price Target$18.90$47.00Market Outperform$0.0000.00% ROIDVAXDynavax Technologies5/7/2025Lower Price Target$9.65$31.00Market Outperform$0.0000.00% ROIANTXAnthem5/5/2025Lower Price Target$1.23$2.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics4/29/2025Reiterated Rating$20.98$46.00Market Outperform$0.0000.00% ROICDTXCidara Therapeutics3/12/2025Set Price Target$22.98$46.00$0.0000.00% ROICVACCureVac2/14/2025Reiterated Rating$3.63$16.00Market Outperform$0.0000.00% ROITPGTPG2/13/2025Reiterated Rating$60.16Market Perform$00.0000.00% ROIESPREsperion Therapeutics2/11/2025Reiterated Rating$1.74$4.00Market Outperform$0.0000.00% ROIENTAEnanta Pharmaceuticals2/11/2025Reiterated Rating$5.64$21.00Market Outperform$00.0000.00% ROIANTXAnthem2/3/2025Reiterated Rating$1.14$5.00Market Outperform$0.0000.00% ROIIRWDIronwood Pharmaceuticals1/30/2025Lower Price Target$3.72$14.00Market Outperform$0.0000.00% ROIESPREsperion Therapeutics1/23/2025Reiterated Rating$2.16$7.00Market Outperform$0.0000.00% ROIABVXAbivax1/10/2025Reiterated Rating$6.63$33.00Market Outperform$000.0000.00% ROIINOInovio Pharmaceuticals1/10/2025Reiterated Rating$2.01$18.00Market Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
